Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, UT 84112, USA.
Cell Metab. 2018 Feb 6;27(2):276-280. doi: 10.1016/j.cmet.2017.12.003. Epub 2018 Jan 4.
The Mayo Clinic recently introduced a diagnostic test that quantifies plasma ceramides in order to identify patients at risk of major adverse cardiac events. By comparing recent discoveries about these biomarker ceramides with the exhaustive body of literature surrounding cholesterol, Summers aims to highlight important advances and critically needed areas of investigation on this exciting class of bioactive lipids.
梅奥诊所最近推出了一种诊断测试,用于定量检测血浆神经酰胺,以识别有发生重大不良心脏事件风险的患者。通过比较关于这些生物标志物神经酰胺的最新发现与围绕胆固醇的广泛文献,萨默斯旨在强调关于这一类生物活性脂质的重要进展和迫切需要研究的领域。